Blair William & Co. IL Sells 534,524 Shares of Phreesia, Inc. (NYSE:PHR)

Blair William & Co. IL lowered its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 78.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 145,450 shares of the company's stock after selling 534,524 shares during the period. Blair William & Co. IL owned approximately 0.25% of Phreesia worth $3,660,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Phreesia by 144.2% during the fourth quarter. JPMorgan Chase & Co. now owns 145,716 shares of the company's stock worth $3,666,000 after buying an additional 86,040 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Phreesia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,823,110 shares of the company's stock valued at $121,349,000 after purchasing an additional 61,048 shares in the last quarter. LPL Financial LLC acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $216,000. KLP Kapitalforvaltning AS purchased a new stake in Phreesia in the 4th quarter valued at approximately $259,000. Finally, Sei Investments Co. increased its position in Phreesia by 8.4% during the fourth quarter. Sei Investments Co. now owns 196,815 shares of the company's stock worth $4,952,000 after buying an additional 15,241 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Price Performance

Shares of PHR traded down $0.96 during mid-day trading on Friday, hitting $23.88. The company's stock had a trading volume of 408,630 shares, compared to its average volume of 430,040. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -16.27 and a beta of 0.82. The firm has a 50-day moving average price of $27.24 and a 200 day moving average price of $24.22. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Remove Ads

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,982 shares of Phreesia stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $105,961.02. Following the transaction, the general counsel now owns 159,137 shares of the company's stock, valued at $4,234,635.57. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Balaji Gandhi sold 1,827 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total transaction of $50,169.42. Following the completion of the transaction, the chief financial officer now owns 103,591 shares in the company, valued at approximately $2,844,608.86. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 164,269 shares of company stock valued at $4,661,469. Corporate insiders own 5.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Piper Sandler reissued an "overweight" rating and issued a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Robert W. Baird decreased their price objective on Phreesia from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. Canaccord Genuity Group increased their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Finally, Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.